Cyplasin-SC(TM) shows proof of efficacy in tumor bearing animals


    EDMONTON, Oct. 12 /CNW/ - Cyplasin-SC(TM) has shown to be an efficient
killer of many tumor cell lines in the laboratory. In previous dose ranging
studies performed by AURIGON Life Sciences, Tutzing, Germany, it was
demonstrated that injection of Cyplasin-SC(TM) into healthy mice at high doses
did not show any negative effects, and the animals remained unharmed. The same
company then proceeded with experiments in order to verify if Cyplasin-SC(TM)
shows efficacy against tumors in animals.
    A specific strain of lab mouse having an impaired immune system was
injected with human melanoma cells. These mice subsequently developed melanoma
tumors having a high resemblance to the real life situation of a natural tumor
in an animal and the tumors were allowed to grow until they had reached a
considerable size.
    Cyplasin-SC(TM) was injected in the vicinity of the tumor, either in a
high dose, or with half of that concentration or with the same solution having
no Cyplasin-SC(TM) added (control solution). Injections were repeated every
third day for 30 days consecutively with the tumor sizes being measured each
time. In order to overcome individual differences, more than 100 mice were
involved in the experiments.
    The final results showed that in those control mice which were injected
with the control solution the tumor reached such a large size that the animals
had to be sacrificed at the end of the experimental period. Mice receiving
either the high dose or the half dose of Cyplasin-SC(TM) saw the growth of
their tumors being arrested soon after the beginning of treatment. Mice which
were given the highest dose of Cyplasin-SC(TM) saw their tumors sizes being
half the size of the tumors as compared to those mice which were treated with
the lower Cyplasin-SC(TM) concentration.
    "The data derived from these experiments are fundamental for the further
development of Cyplasin-SC as an efficient tumor drug", said Professor
Christian Petzelt, CSO of Cyplasin Biomedical Ltd. "First, they demonstrate
the efficacy of Cyplasin-SC for treating human melanoma, and second, they show
the clear dose dependency of the drug. As required by Good Laboratory Practice
Guidelines (GLP), all these experiments will now be repeated." After their
successful completion, the development of Cyplasin-SC(TM) will move into the
animal toxicology testing phase before IND submission and the resultant
initiation of phase I, experiments involving humans.

    About Melanoma

    Market statistics for skin cancer and melanoma show that melanoma
currently affects more then 2.4 million people worldwide. In the US more than
62,000 new cases are reported every year, as fair-skinned and Sunbelt
populations are at high risk for the disease. Australia has the highest rate
of melanoma in the world among males and has the second highest rate in the
world among females (Australia's Health 2004, AIHW). Overall the world wide
incidence has doubled over the past 20 years.

    About Cyplasin-SC(TM)

    In laboratory tests Cyplasin-SC(TM) has demonstrated a selective ability
to rapidly kill melanoma cancer cells while leaving normal non-cancerous cells
untouched. In animal efficacy studies Cyplasin-SC has demonstrated efficacy
for melanoma in a dose related response. Cyplasin is a protein originally
discovered and isolated by Professor Petzelt from a marine organism, the sea
hare (Aplysia punctata). The protein is manufactured as a recombinant protein
which allows the company to develop the protein as a potential anticancer
therapeutic product. Patents have been issued to the Company covering the
Cyplasin protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Alberta, Canada with a
research laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM) for
skin cancers and melanomas. CBL is publicly traded (CYPL: OTCBB)

    Forward-Looking Statements

    This Press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news

For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., Direct phone (780) 469-CYPL(2975), Email Address:, FAX Number (780) 699-7933, Website URL:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890